Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Disease × Magnetic Resonance Spectroscopy × Clear all

Phase

Phase 3 3 Phase NA 2 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 30 Prostatic Neoplasms 17 Lung Neoplasms 16 Breast Neoplasms 16 Carcinoma, Non-Small-Cell Lung 15 Colorectal Neoplasms 14 Glioblastoma 13 Multiple Myeloma 12 Pancreatic Neoplasms 10 Carcinoma, Renal Cell 10 Lymphoma, Large B-Cell, Diffuse 9 Lymphoma, Follicular 9 Glioma 9 Brain Neoplasms 9 Melanoma 8 Leukemia, Lymphocytic, Chronic, B-Cell 8 Triple Negative Breast Neoplasms 7 Carcinoma, Hepatocellular 7 Ovarian Neoplasms 6 Neoplasms 6 Lymphoma, Non-Hodgkin 6 Lymphoma, B-Cell, Marginal Zone 6 Lymphoma, B-Cell 6 Carcinoma 6 Astrocytoma 6 Uterine Cervical Neoplasms 5 Stomach Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Oropharyngeal Neoplasms 5 Neuroendocrine Tumors 5

Interventions

Dexamethasone 2 vistusertib 1 ricolinostat 1 pomalidomide 1 irinotecan sucrosofate 1 daratumumab 1 bermekimab 1 atezolizumab 1 alovudine 1 TKM-080301 1 TIC10 compound 1 Prostatectomy 1 Pluvicto 1 Magnetic Resonance Spectroscopy 1 Lenalidomide 1 Ipilimumab 1 Ga(III)-DOTATOC 1 Fluorouracil 1 Cyclophosphamide 1 Blood Specimen Collection 1 (225)Ac-PSMA-617 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00633958 2021-10-20

FLT

Dana-Farber Cancer Institute

Phase 1 Terminated

Disease, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡